Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a …
Background Preoperative identification of tumour type could have important implications for
the choice of treatment for renal cancers. Antibody cG250 reacts against carbonic anhydrase-…
the choice of treatment for renal cancers. Antibody cG250 reacts against carbonic anhydrase-…
Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes
…, G Heller, C May, V Ponomarev, S Ruan… - Nature …, 2003 - nature.com
New technologies are needed to characterize the migration, survival, and function of antigen-specific
T cells in vivo. Here, we demonstrate that Epstein-Barr virus (EBV)–specific T cells …
T cells in vivo. Here, we demonstrate that Epstein-Barr virus (EBV)–specific T cells …
First-in-humans imaging with 89Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion …
…, JA O'Donoghue, M Ziolkowska, S Ruan… - Journal of Nuclear …, 2020 - Soc Nuclear Med
Immunotherapy is becoming the mainstay for treatment of a variety of malignancies, but only
a subset of patients responds to treatment. Tumor-infiltrating CD8-positive (CD8+) T …
a subset of patients responds to treatment. Tumor-infiltrating CD8-positive (CD8+) T …
Dependence of FDG uptake on tumor microenvironment
A Pugachev, S Ruan, S Carlin, SM Larson… - International Journal of …, 2005 - Elsevier
Purpose: To investigate the factors affecting the 18 F-fluorodeoxyglucose ( 18 F-FDG) uptake
in tumors at a microscopic level, by correlating it with tumor hypoxia, cellular proliferation, …
in tumors at a microscopic level, by correlating it with tumor hypoxia, cellular proliferation, …
Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu (II)-diacetyl-bis (N4-methylthiosemicarbazone) positron emission tomography …
…, S Cai, E Burnazi, RD Finn, P Burgman, S Ruan… - International Journal of …, 2005 - Elsevier
Purpose: To compare two potential positron emission tomography (PET) tracers of tumor
hypoxia in an animal model. Methods and Materials: The purported hypoxia imaging agents 18 …
hypoxia in an animal model. Methods and Materials: The purported hypoxia imaging agents 18 …
89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer
…, V Beylergil, S Lyashchenko, S Ruan… - European journal of …, 2014 - Springer
Purpose Given the bone tropism of prostate cancer, conventional imaging modalities poorly
identify or quantify metastatic disease. Zr-huJ591 positron emission tomography (PET) …
identify or quantify metastatic disease. Zr-huJ591 positron emission tomography (PET) …
First-in-human imaging with 89Zr-Df-IAB2M anti-PSMA minibody in patients with metastatic prostate cancer: pharmacokinetics, biodistribution, dosimetry, and lesion …
N Pandit-Taskar, JA O'Donoghue, S Ruan… - Journal of Nuclear …, 2016 - Soc Nuclear Med
We conducted a phase I dose-escalation study with 89 Zr-desferrioxamine-IAB2M ( 89 Zr-IAB2M),
an anti–prostate-specific membrane antigen minibody, in patients with metastatic …
an anti–prostate-specific membrane antigen minibody, in patients with metastatic …
First-in-human human epidermal growth factor receptor 2–targeted imaging using 89Zr-Pertuzumab PET/CT: dosimetry and clinical application in patients with breast …
…, SK Lyashchenko, C Riedl, S Ruan… - Journal of Nuclear …, 2018 - Soc Nuclear Med
In what we believe to be a first-in-human study, we evaluated the safety and dosimetry of 89
Zr-pertuzumab PET/CT for human epidermal growth factor receptor 2 (HER2)–targeted …
Zr-pertuzumab PET/CT for human epidermal growth factor receptor 2 (HER2)–targeted …
Pharmacokinetics, biodistribution, and radiation dosimetry for 89Zr-trastuzumab in patients with esophagogastric cancer
…, SM Larson, V Beylergil, S Ruan… - Journal of Nuclear …, 2018 - Soc Nuclear Med
Trastuzumab with chemotherapy improves clinical outcomes in patients with human
epidermal growth factor receptor 2 (HER2)–positive esophagogastric adenocarcinoma (EGA). …
epidermal growth factor receptor 2 (HER2)–positive esophagogastric adenocarcinoma (EGA). …
Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal …
…, PJ Kothari, RD Finn, P Zanzonico, S Ruan… - Nuclear medicine and …, 2002 - Elsevier
Radionuclide labeled somatostatin analogues selectively target somatostatin receptor (SSTR)-expressing
tumors as a basis for diagnosis and treatment of these tumors. Recently, a …
tumors as a basis for diagnosis and treatment of these tumors. Recently, a …